Physician

Christine Gail Simone, M.D.

According to 2025 Medicare claims, Christine Simone, M.D. (NPI: 1649591660) practices hematology/oncology in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from Martin, FL. This provider's primary affiliated billing organization is STUART ONCOLOGY ASSOCIATES, PA (NPI: 1902858822; TIN: 592003116) and primary practice location at 34952-7558.

Simone's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 712 traditional Medicare patients, billed 257,622 HCPCS/CPT codes, and received $4,270,717 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,932 prescription claims across 468 beneficiaries totaling $6,484,848 in drug costs, led by Tagrisso (Osimertinib Mesylate). 2023 DME data shows 37 claims. Open Payments data shows 207 records totaling $4,379. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $115,332 to $4,270,717. Similarly, Part D prescription costs have moved sharply higher in recent years, from $50,031 to $6,484,848. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	151	8,517	$115,332
2017	317	44,540	$530,443
2018	566	154,618	$2,290,967
2019	643	166,904	$2,744,465
2020	624	170,692	$3,153,892
2021	615	136,809	$2,228,170
2022	655	133,296	$2,224,990
2023	713	166,230	$2,941,110
2024	712	257,622	$4,270,717

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	27	79	$50,031
2017	181	722	$515,506
2018	238	1,358	$1,447,554
2019	300	1,481	$1,624,040
2020	332	1,740	$2,209,012
2021	357	1,702	$2,440,844
2022	366	1,705	$3,175,722
2023	414	2,085	$3,345,763
2024	468	2,932	$6,484,848

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	11	$430
2023	N/R	37	$665
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	453	1,574	$98
82607	Cyanocobalamin (vitamin b-12) level	156	312	$15
80053	Blood test, comprehensive group of blood chemicals	359	1,322	$10
36415	Insertion of needle into vein for collection of blood sample	383	1,482	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	425	2,302	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	38	1,140	$646,013
Calquence	Acalabrutinib Maleate	28	960	$477,875
Ibrance	Palbociclib	29	812	$455,432
Keytruda	Pembrolizumab	36	756	$403,666
Revlimid	Lenalidomide	27	736	$402,007

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	207	$4,379	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christine Gail Simone, M.D.?

Tedicare shows public-source Medicare data for Christine Gail Simone, M.D. (NPI 1649591660), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christine Gail Simone, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christine Gail Simone, M.D.?

Christine Gail Simone, M.D. is linked to STUART ONCOLOGY ASSOCIATES, PA (billing NPI 1902858822) in the available physician profile data.

Does Christine Gail Simone, M.D. have Open Payments data?

Christine Gail Simone, M.D. has 207 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.